About HilleVax
HilleVax is a company based in Boston (United States) founded in 2021 by David Socks. HilleVax has raised $135 million across 1 funding round from investors including Lightspeed Venture Partners, Franklin Templeton and RA Capital. The company has 14 employees as of December 31, 2024. HilleVax offers products and services including Norovirus Vaccine. HilleVax operates in a competitive market with competitors including Savara Pharma, VBI Vaccines, Icosavax, Precigen and Intercell, among others.
- Headquarter Boston, United States
- Employees 14 as on 31 Dec, 2024
- Founders David Socks
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hillevax, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$147.27 M (USD)-19.18as on Dec 31, 2024
-
EBITDA
-$103.76 M (USD)20.91as on Dec 31, 2024
-
Total Equity Funding
$135 M (USD)
in 1 rounds
-
Latest Funding Round
$135 M (USD), Series D
Sep 08, 2021
-
Investors
Lightspeed Venture Partners
& 12 more
-
Employee Count
14
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of HilleVax
HilleVax is a publicly listed company on the NASDAQ with ticker symbol HLVX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of HilleVax
HilleVax offers a comprehensive portfolio of products and services, including Norovirus Vaccine.
Vaccine to prevent norovirus infections and reduce gastroenteritis outbreaks worldwide.
People of HilleVax
Unlock access to complete
Unlock access to complete
Funding Insights of HilleVax
HilleVax has successfully raised a total of $135M through 1 strategic funding round. The most recent funding activity was a Series D round of $135 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HilleVax
HilleVax has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Lightspeed Venture Partners, Franklin Templeton and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for HilleVax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HilleVax
Investment portfolio details for HilleVax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HilleVax
Detailed financials for HilleVax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hillevax Comparisons
Peer comparison for HilleVax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HilleVax
HilleVax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Savara Pharma, VBI Vaccines, Icosavax, Precigen and Intercell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare respiratory diseases are developed by Savara Pharma.
|
|
| Locked | Locked | Locked |
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
|
| Locked | Locked | Locked |
Developer of computationally designed VLP vaccines for treating multiple infections
|
|
| Locked | Locked | Locked |
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases, including antigens and adjuvants, were developed.
|
Detailed competitors of HilleVax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hillevax
Complete news archive for HilleVax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HilleVax
HilleVax was founded in 2021.
HilleVax is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
HilleVax is a funded company, having raised a total of $135M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at HilleVax is 14.
HilleVax was founded in 2021 and is based in Boston, United States. Focus is placed on biotechnology, specifically the development of vaccines against norovirus. The lead product, HIL-214, is a bivalent virus-like particle vaccine targeting GI.1 and GII.4 strains. Active immunization is provided to prevent acute gastroenteritis caused by norovirus, with operations centered on clinical advancement in the vaccine sector.
HilleVax's top competitors include Savara Pharma, VBI Vaccines and Sinovac.
HilleVax offers Norovirus Vaccine.
Yes, HilleVax is publicly traded on NASDAQ under the ticker symbol HLVX.
HilleVax has 13 investors. Key investors include Lightspeed Venture Partners, Franklin Templeton, RA Capital, Frazier Healthcare Partners, and Perceptive Advisors.
The ticker symbol of HilleVax is HLVX on NASDAQ.